

Biocon Biologics Limited

CIN: U24119KA2016PLC093936
Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN
T +91 080-6775 6775, **F** +91 080-6775 1030
E contact@bioconbiologics.com
www.bioconbiologics.com

July 6, 2026

Singapore Exchange Securities Trading Limited
2 Shenton Way #02-00
SGX Centre 1
Singapore 068804

Notice of Issuer Substitution in relation to the US\$800,000,000 6.67% Senior Secured Notes due 2029 (ISIN: US090978AA56 for Rule 144A Notes; ISIN: USG11185AA61 for Regulation S Notes)

Biocon Biologics Global PLC announces that it has received in-principle approval from the SGX-ST on 1 July 2026 with respect to its substitution by Biocon Biologics UK PLC (*formerly known as Biosimilars Newco Limited*) as the issuer of the US\$800,000,000 6.67% Senior Secured Notes due 2029 (ISIN: US090978AA56 for Rule 144A Notes; ISIN: USG11185AA61 for Regulation S Notes) (the “**Notes**”) originally issued by Biocon Biologics Global PLC under indenture dated October 9, 2024 executed among Biocon Biologics Global PLC as the issuer, Biocon Biologics Limited, Biocon Biologics International Limited, UK (*formerly known as Biocon Biologics UK Limited*), Biocon Biologics UK PLC (*formerly known as Biosimilars Newco Limited*), Biocon Sdn. Bhd., and Biocon Biologics Ireland Limited (*formerly known as Biosimilar Collaborations Ireland Limited*) as the guarantors, and Citicorp International Limited as trustee and collateral agent (the “**Indenture**” and such substitution, the “**Issuer Substitution**”).

Biocon Biologics UK PLC is a subsidiary of Biocon Biologics Limited and Biocon Biologics Global PLC is a step-down subsidiary of Biocon Biologics Limited.

Approval in-principle has been received from the Singapore Exchange Securities Trading Limited (SGX-ST) for the Issuer Substitution.

The SGX-ST assumes no responsibility for the correctness of any of the statements made or opinions expressed or reports contained herein or in any offering documents relating to the Notes. Approval in-principle of the SGX-ST for the Issuer Substitution is not to be taken as an indication of the merits of Biocon Biologics UK PLC, Biocon Biologics Global PLC, their respective subsidiaries, their respective associated and/or joint venture companies (if any) or the Notes.

Further information on the Issuer Substitution is set out in the attached intimation of Issuer Substitution given to Citicorp International Limited as trustee and collateral agent under the Indenture.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

AKHILES
H NAND
Digitally signed by
AKHILESH NAND
Date: 2026.07.06
11:20:08 +05'30'

Akhilesh Nand
Company Secretary
Membership No. ACS 13669